{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:45:52Z","timestamp":1793295952642,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ajem.2020.04.035","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T11:13:16Z","timestamp":1586949196000},"page":"1488-1493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Pharmacotherapy in COVID-19; A narrative review for emergency providers"],"prefix":"10.1016","volume":"38","author":[{"given":"Nikita","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Mazer-Amirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Alkindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Pourmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajem.2020.04.035_bb0005","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"10.1016\/j.ajem.2020.04.035_bb0010","author":"Centers for Disease Control and Prevention"},{"issue":"20","key":"10.1016\/j.ajem.2020.04.035_bb0015","first-page":"30116","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"2600","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ajem.2020.04.035_bb0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/j.ajem.2020.04.035_bb0025","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2020.04.035_bb0030","doi-asserted-by":"crossref","unstructured":"Sanville B, Corbett R, Pidcock W, et al. A community transmitted case of severe acute respiratory distress syndrome due to SARS CoV2 in the United States. Clin Infect Dis https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa347\/5813637; 2020 [accessed 12 April 2020].","DOI":"10.1093\/cid\/ciaa347"},{"issue":"1","key":"10.1016\/j.ajem.2020.04.035_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajem.2020.04.035_bb0045","author":"Liverpool Drug Interactions"},{"key":"10.1016\/j.ajem.2020.04.035_bb0050","author":"Gilead"},{"key":"10.1016\/j.ajem.2020.04.035_bb0055","author":"Chen"},{"issue":"5","key":"10.1016\/j.ajem.2020.04.035_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses-drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.ajem.2020.04.035_bb0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajem.2020.04.035_bb0070","author":"Hoffmann"},{"issue":"3","key":"10.1016\/j.ajem.2020.04.035_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ajem.2020.04.035_bb0080","first-page":"1","article-title":"A trial of Lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajem.2020.04.035_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3346\/jkms.2020.35.e89","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.ajem.2020.04.035_bb0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ajem.2020.04.035_bb0095","first-page":"1","article-title":"Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"2019","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.ajem.2020.04.035_bb0100","first-page":"1","article-title":"Novel 2019 coronavirus SARS-CoV-2 (COVID-19): an updated overview for emergency clinicians","volume":"22","author":"Giwa","year":"2020","journal-title":"Emerg Med Pract"},{"key":"10.1016\/j.ajem.2020.04.035_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.ajem.2020.04.035_bb0110","author":"World Health Organization"},{"issue":"1","key":"10.1016\/j.ajem.2020.04.035_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ajem.2020.04.035_bb0120","first-page":"1","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit","volume":"2","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2020.04.035_bb0125","first-page":"1","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial Philippe Gautret","author":"Gautret","year":"2020","journal-title":"Mediterr Infect"},{"issue":"12","key":"10.1016\/j.ajem.2020.04.035_bb0130","doi-asserted-by":"crossref","first-page":"2264.e5","DOI":"10.1016\/j.ajem.2019.158387","article-title":"Toxicokinetics of hydroxychloroquine following a massive overdose","volume":"37","author":"de Olano","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2020.04.035_bb0135","unstructured":"U.S. Food and Drug Administration. Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic National Stockpile for treatment of 2019 coronavirus disease. https:\/\/www.fda.gov\/media\/136534\/download; 2020 [accessed 30 March 2020]."},{"key":"10.1016\/j.ajem.2020.04.035_bb0140","author":"The Hill"},{"key":"10.1016\/j.ajem.2020.04.035_bb0145","author":"American Society of Health Systems Pharmacists"},{"issue":"10223","key":"10.1016\/j.ajem.2020.04.035_bb0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2020.04.035_bb0155","first-page":"1","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ajem.2020.04.035_bb0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13054-020-2818-6","article-title":"Treatment of COVID-19: old tricks for new challenges","volume":"24","author":"Cunningham","year":"2020","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.ajem.2020.04.035_bb0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ajem.2020.04.035_bb0170","first-page":"1","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"10.1016\/j.ajem.2020.04.035_bb0175","first-page":"1","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"issue":"March","key":"10.1016\/j.ajem.2020.04.035_bb0180","doi-asserted-by":"crossref","first-page":"m1256","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"1256","author":"Tanne","year":"2020","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.ajem.2020.04.035_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.ajem.2020.04.035_bb0190","first-page":"1","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2020.04.035_bb0195","author":"Bertisch"},{"issue":"8","key":"10.1016\/j.ajem.2020.04.035_bb0200","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/135965350601100803","article-title":"Indomethacin has a potent antiviral activity against SARS coronavirus","volume":"11","author":"Amici","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ajem.2020.04.035_bb0205","series-title":"HFSA\/ACC\/AHA statement addresses concerns re: Using RAAS antagonists in COVID-19","author":"American College of Cardiology","year":"2020"},{"issue":"9","key":"10.1016\/j.ajem.2020.04.035_bb0210","article-title":"Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig","volume":"53","author":"Basu","year":"2020","journal-title":"bioRxiv"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675720302631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675720302631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:48:18Z","timestamp":1760024898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675720302631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0735675720302631"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2020.04.035","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy in COVID-19; A narrative review for emergency providers","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2020.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}